PPP2R5D-Related Neurodevelopmental Disorder and Multiple Haemangiomas: A Novel Phenotypic Trait?
Open Access
- 16 December 2024
- journal article
- case report
- Published by MDPI AG in Pediatric Reports
- Vol. 16 (4) , 1200-1206
Abstract
Background: Houge-Janssens syndrome 1 is a condition with onset in early childhood caused by heterozygous pathogenic variants in the PPP2R5D gene, which encodes a B56 regulatory subunit of the serine/threonine protein phosphatase 2A (PP2A). There is evidence that the PP2A-PPP2R5D complex is involved in regulating the phosphatidylinositol 3-kinase (PI3K)/AKT signalling pathway, which is crucial for several cellular processes, including the pathogenesis and progression of haemangiomas. Case presentation: We report the first PPP2R5D-related neurodevelopmental disorder case from Sardinia, a child with transient hypoglycaemia, facial dysmorphisms, and multiple haemangiomas. Whole Exome Sequencing analysis confirmed the clinical suspicion, detecting the presence of the de novo missense variant c.592G>A in the PPP2R5D gene. Conclusions: Haemangiomas have never been linked to the syndromic phenotype of the PPP2R5D-associated disorder. The close correlation between the PP2A enzyme and the PI3K/AKT signalling pathway suggests the possible correlation between its dysfunction and activation of haemangiogenesis. Our report highlights a possible link between the PPP2R5D-related disorder and altered angiogenesis, characterizing diffuse haemangiomas as a possible novel phenotypic trait of this condition.Keywords
This publication has 35 references indexed in Scilit:
- Hypoglycemia due to PI3K/AKT/mTOR signaling pathway defects: two novel cases and review of the literatureHormones, 2021
- Phosphoinositide 3‐kinase: a new kid on the block in vascular anomaliesThe Journal of Pathology, 2016
- De novo missense variants in PPP2R5D are associated with intellectual disability, macrocephaly, hypotonia, and autismneurogenetics, 2015
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- PIK3CA‐related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluationAmerican Journal of Medical Genetics Part A, 2014
- Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancerCancer Letters, 2013
- PI3K/PTEN signaling in tumorigenesis and angiogenesisBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2008
- PP2A: the expected tumor suppressorCurrent Opinion in Genetics & Development, 2005
- Type 2A protein phosphatase, the complex regulator of numerous signaling pathwaysBiochemical Pharmacology, 2000
- Comparison of heterotrimeric protein phosphatase 2A containing different B subunits.Journal of Biological Chemistry, 1994